Jean-Michel Dogné on The Aspirin Dosing after Trump’s Announcement
Jean-Michel Dogné, Full Professor and Dean of the Faculty of Medicine at Namur University, shared on LinkedIn:
”Approximations and blatant errors…
From the great Trump
- The aspirin (ASA) does not “thin” or “liquefy” the blood!
Acetylsalicylic acid has no effect on blood viscosity.
Its mechanism of action is well known:
- inhibition of platelet aggregation,
- by irreversibly blocking platelet COX-1,
- leading to a decrease in thromboxane A₂ synthesis.
Talking about “thick blood” or “thin blood” is therefore a misleading simplification with no pathophysiological basis.
2. In cardiovascular (secondary) prevention, we are not talking about high doses!
The recommendations are very clear:
- Low-dose ASA, generally 75 to 100 mg per day.
Furthermore, in patients aged ≥ 70 with no history of cardiovascular disease, data show no net benefit from low-dose ASA and a significant increase in major bleeding!
In practice, the recommendations therefore advise against initiating ASA for primary prevention in these patients.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia